Medicare Part D stand-alone prescription drug plans serve a majority of rural Medicare beneficiaries, with premium stabilization efforts influencing plan availability and affordability in 2025 and beyond.
UnitedHealth Group lowers its 2025 revenue forecast due to increased Medicare Advantage plan usage, signaling shifts in health insurance market trends and consumer preferences.
CMS finalizes key aspects of the 2026 Medicare Advantage and Part D programs rule, including expanded insulin coverage, payment plans, and new pharmacy requirements for network participation.
Elevance Health lowers full-year profit forecast despite Q1 revenue growth driven by higher premiums and membership gains in Medicare Advantage and ACA.
Elevance Health reports 15% revenue growth in Q1 2025 driven by Medicare Advantage expansion, premium increases, and CarelonRx portfolio growth, highlighting ongoing healthcare market evolution.
President Trump's executive order prompts potential changes in Medicare drug price negotiation, affecting pharmaceutical pricing, Medicare spending, and FDA drug import regulations. Epic Systems also shifts to a more public presence in healthcare IT.
Analysis of Medicare affordability challenges highlights systemic issues and the need for reform in traditional Medicare and Medicare Advantage plans affecting coverage and costs.
CMS finalizes critical 2026 Medicare Advantage rule changes, including anti-obesity drug coverage exclusion, AI regulatory deferral, and limits on retroactive inpatient stay denials affecting payers and providers.
Elevance Health reports steady Q1 profits with growth in Medicare Advantage and Carelon despite elevated medical costs and legal challenges.
Elevance Health's Q1 report shows Medicare Advantage utilization in line with expectations, Medicaid rate progress, and ACA expansion amid market volatility.
